Stockreport

Immune Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for Bertilimumab for the Treatment of Bullous Pemphigoid

IMMUNE PHARMACEUTICALS INC NE  (IMNP) 
US:NASDAQ Investor Relations: immunepharma.com/investor-relations
PDF ENGLEWOOD CLIFFS, N.J., July 30, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developin [Read more]